Through various measures and modifications, all systems and manufacturing processes have been successfully integrated into Vetter’s business operations and the site is now ready for operations, according to company managing director, Thomas Otto.
“With this additional facility we will further expand our capability for early clinical development for phase I and phase II drug candidates,” add Peter Soelkner, also a managing director at the CDMO. “The dedicated manufacturing site will focus on supporting our customers on quality, timeliness and technical expertise.”
The production site currently offers 100,000 square feet of offices, laboratory space, areas for material preparation as well as room temperature, cool and frozen storage, and one automated vial filling line for liquid and lyophilized products.
In the coming months, media fills for different vial formats will be performed onsite that simulate the actual drug manufacturing process and represent an important step in preparing for future customers projects.
“When establishing the new location, Vetter’s general expertise in aseptic manufacturing processes was, of course, very valuable,” outlines Claus Feussner, PhD, senior vice president Vetter Development Service. “However, another major contributing factor was the know-how and experience we gained over the last ten years at our successfully established US Development Service facility in Chicago. These will be incorporated into the customer business and future production for in human trials in Rankweil.”
The next milestone for the new clinical site will be the official GMP inspection for obtaining the manufacturing license in the beginning of the fourth quarter 2021. The authority responsible for this site is the Austrian BASG/AGES (Federal Office for Safety in Health newsCare /Agency for Health and Food Safety).
